Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma

Talal El Zarif et al.

Renal cell carcinoma with sarcomatoid differentiation (sRCC) is associated with poor survival and a heightened response to immune checkpoint inhibitors (ICIs). Two major barriers to improving outcomes for sRCC are the limited understanding of its gene regulatory programs and the low diagnostic yield of tumor biopsies due to spatial heterogeneity. Herein, we characterized the epigenomic landscape of sRCC by profiling 107 epigenomic libraries from tissue and plasma samples from 50 patients with RCC and healthy volunteers. By profiling histone modifications and DNA methylation, we identified highly recurrent epigenomic reprogramming enriched in sRCC. Furthermore, CRISPRa experiments implicated the transcription factor FOSL1 in activating sRCC-associated gene regulatory programs, and FOSL1 expression was associated with the response to ICIs in RCC in two randomized clinical trials. Finally, we established a blood-based diagnostic approach using detectable sRCC epigenomic signatures in patient plasma, providing a framework for discovering epigenomic correlates of tumor histology via liquid biopsy.

Tags
MagMeDIP kit
Antibody
IPure kit

Share this article
Tweet

Published
June, 2024

Source

Products used in this publication

C02010021

MagMeDIP qPCR Kit
C03010015

IPure kit v2
C15410196

H3K27ac Antibody - ChIP-seq Grade
C15410035

H3K4me2 Antibody - ChIP-seq Grade
C02040012

DNA Methylation control package

Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma

Products used in this publication

MagMeDIP qPCR Kit

IPure kit v2

H3K27ac Antibody - ChIP-seq Grade

H3K4me2 Antibody - ChIP-seq Grade

DNA Methylation control package

活动